Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men.
Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E; West of Scotland Coronary Prevention Study. Skogsberg J, et al. Among authors: mcmahon ad. J Intern Med. 2003 Dec;254(6):597-604. doi: 10.1111/j.1365-2796.2003.01236.x. J Intern Med. 2003. PMID: 14641801 Free article. Clinical Trial.
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Polisecki E, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Blauw GJ, Westendorp RG, de Craen AJ, Trompet S, Buckley BM, Murphy MB, Ordovas JM, Schaefer EJ; PROSPER Study Group. Polisecki E, et al. Among authors: mcmahon ad. Atherosclerosis. 2008 Sep;200(1):95-101. doi: 10.1016/j.atherosclerosis.2007.12.005. Epub 2008 Feb 8. Atherosclerosis. 2008. PMID: 18262190 Free PMC article. Clinical Trial.
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ. Boekholdt SM, et al. Among authors: mcmahon ad. Circulation. 2005 Jan 25;111(3):278-87. doi: 10.1161/01.CIR.0000153341.46271.40. Epub 2005 Jan 17. Circulation. 2005. PMID: 15655129
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Westendorp RG, de Craen AJ, Buckley BM, Ordovas JM, Schaefer EJ; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. Polisecki E, et al. Among authors: mcmahon ad. Atherosclerosis. 2008 Sep;200(1):109-14. doi: 10.1016/j.atherosclerosis.2007.12.004. Epub 2008 Feb 7. Atherosclerosis. 2008. PMID: 18261733 Free PMC article. Clinical Trial.
128 results